FDA Approves 20mg and 80mg Dosages of Celltrion’s Yuflyma®, Biosimilar to AbbVie’s Humira® (adalimumab)

FDA has approved Celltrion’s Yuflyma® in 20mg (pre-filled syringe) and 80mg (pre-filled autoinjector and pre-filled syringe) dosages, in addition to the 40mg dose approved on 24 May 2023.

The Celltrion 80mg adalimumab auto-injector and pre-filled syringe were approved by Healthcare Canada on 30 August 2023.